20,295 reports of this reaction
6.5% of all TREPROSTINIL reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for TREPROSTINIL, manufactured by United Therapeutics Corporation. There are 20,295 FDA adverse event reports linking TREPROSTINIL to DYSPNOEA. This represents approximately 6.5% of all 313,927 adverse event reports for this drug.
TREPROSTINIL has an overall safety score of 85 out of 100. Patients taking TREPROSTINIL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among TREPROSTINIL users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for TREPROSTINIL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 20,295 FDA reports for TREPROSTINIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 6.5% of all adverse event reports for TREPROSTINIL, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking TREPROSTINIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.